ILTS Insights: Markers of rejection and of tolerance in liver transplantation current tools and futures candidates
Join the ILTS Webinar on "Markers of rejection and of tolerance in liver transplantation current tools and futures candidates" on Dec 7! Philip Halloran, Josh Levitsky, Alberto Sanchez-Fueyo will discuss the different types of rejection, new tools for diagnosis, and best therapeutic options.
ILTS INSIGHTS: Markers of rejection and of tolerance in liver transplantation current tools and futures candidates
Available on demand: ILTS Education Page
This webinar will focus on the different types of rejection, as well as discuss new tools for diagnosis and the best therapeutic options. Despite the improvement of immunosuppression strategies, allograft rejection remains an issue affecting liver transplant recipients. Markers of rejection can improve early diagnosis and can help to tailor immunosuppression. Antibody-mediated rejection is more and more recognized after LT, however, its prevention, diagnosis, and treatment are still challenging.
This webinar is organized by the Liver Transplant Immunology SIG & Precision Medicine and Biomarkers in Liver Transplantation SIG.
Objectives: Review the markers of rejection used in clinical practice and discuss new potential markers; discuss therapeutic immunosuppression monitoring and tailoring; identify the patients who are candidates to immunosuppression withdrawal.
- Liver transcriptomic approach to allograft dysfunction (Philip Halloran)
- Biomarkers of rejection (Josh Levitsky)
- Can we predict immune tolerance? (Alberto Sanchez-Fueyo)
Philip F Halloran is a Professor at the Department of Medicine Division of Nephrology at the University of Alberta. He is a nephrologist – researcher with a focus on organ transplantation and organ diseases, at both the clinical and basic levels. His research interests include the mechanisms of organ transplant rejection and injury, and the development of treatments to improve outcomes in transplantation and primary organ diseases.
|Josh Levitsky is currently the Gastroenterology and Transplant Hepatology Fellowship Program Director and Director of Liver Transplant Research at the Northwestern University Feinberg School of Medicine. Dr. Levitsky’s academic interests are clinical and translational in nature, with a focus on liver transplant immunosuppression, tolerance, and biomarkers. He is the principal and co-investigator for a number of NIH, pharmaceutical, and investigator-initiated trials.|
|Alberto Sanchez-Fueyo is a Professor in Hepatology at the King’s College in London. His research is focused on understanding the mechanisms responsible for immunological tolerance in transplantation and developing novel immunotherapies in liver diseases.|
|Eleonora De Martin is a Hepatologist at Centre-Hépato-Biliaire, Paul Brousse Hospital, France. Her fields of expertise are liver transplantation, autoimmune hepatitis in particular severe acute forms with LT indication and hepatic toxicity of immunotherapy for metastatic cancer. She is the Chair-elect of the ILTS Vanguard Committee and topic coordinator of the ILTS Liver Transplant Immunology Special Interest Group.|
|Sunil Kurian is a Research Scientist at the Division of Organ Transplant and is part of the Biorepository and Bioinformatics core at Scripps Health, San Diego. He is part of the team that works on both clinical and molecular diagnostics of liver donor organ quality as part of the Liver Outcomes Monitoring Registry (LOMR) in conjunction with UNOS. Dr. Kurian is a Topic Coordinator of the ILTS Precision Medicine and Biomarkers in Liver Transplantation SIG.|
This webinar is supported by: Chiesi Farmaceutici S.p.A.
The production of this webinar was made possible with the unconditional grant of Chiesi Farmaceutici. Chiesi has had no influence on the content, and full editorial control remains the sole responsibility of ILTS.
|Chiesi is an international company based in Parma, Italy, with more than 85 years of experience and a strong focus on research, development, production, and the commercialisation, of innovative medicines in the Respiratory, Neonatology, Rare Disease, and Special Care Therapeutic Areas. Since 2019, Chiesi is the largest global pharmaceutical group awarded with B Corp certification, recognition of the highest standards of social and environmental performance and transparency.|